Affiliations 

  • 1 Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Japan. Electronic address: akihirot@hama-med.ac.jp
  • 2 Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • 3 Transfusion Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 4 Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 5 Blood Bank, Taksin Hospital, Medical Service Department of Bangkok Metropolitan, Bangkok, Thailand
  • 6 Blood Bank, Prince of Wales Hospital, Hong Kong Special Administrative Region
  • 7 Transfusion Medicine, Southwest Hospital, Third Military Medical University, Chongqing, China
  • 8 Seegene Medical Foundation, Seoul, South Korea
  • 9 Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Soul, South Korea
  • 10 Laboratory Medicine, Kyungpook National University Hospital, Kyungpook National University, School of Medicine, Daegu, South Korea
  • 11 Laboratory Medicine, Yonsei University College of Medicine, Soul, South Korea
  • 12 Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
  • 13 Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan
  • 14 Center for Transfusion Medicine and Cell Therapy, Tokyo Medical and Dental University, Tokyo, Japan
  • 15 Department of Transfusion Medicine, Saga University, Saga, Japan
  • 16 Laboratory Medicine, Asahikawa Medical University, Asahikawa, Japan
  • 17 Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan
Transfus Apher Sci, 2020 Oct;59(5):102944.
PMID: 33228922 DOI: 10.1016/j.transci.2020.102944

Abstract

As an East-Asian international study, we evaluated erythrocyte alloimmunity by gender and history of transfusion or pregnancy. In total, data from more than 1,826,000 patients were analyzed, from whom 26,170 irregular erythrocyte antibodies were detected in 22,653 cases. Antibody frequencies in these cases were as follows: anti-E, 26.8%; anti-Lea, 20.0%; anti-P1, 7.1%; anti-M, 6.4%; anti-Mia, 5.6%; anti-c + E, 5.6%; anti-Leb, 4.6%; anti-D, 2.8%; anti-Fyb, 2.6%; anti-Lea+Leb, 2.5%; anti-Dia, 2.0%; and others. For pregnant patients, anti-D (12.7%) was statistically more frequent. For transfused patients, anti-E (37.3%), anti-c + E (9.5%), anti-C + e (3.3%) and anti-Jka (3.1%) were significantly more frequent.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.